Pay in 4 interest-free payments of $6.70 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
Epub 2022 May 13
Multiple randomized controlled trials and real-world studies have shown that adding a GLP-1 agonist to metformin achieves significantly greater weight loss and A1C reduction than metformin alone
doi: 10.1016/j.molmet.2020.101102 11 MllerTDFinanBBloomSRD'AlessioDDruckerDJFlattPRet al
We recommend patients work with their Willow physician to slowly decrease their dose in order to maintain their weight loss achievements
As PTDM and chronic kidney disease are prevalent comorbidities in liver transplant patients, and with the increasing trend of obesity, it is crucial to further investigate and understand the potential benefits and challenges of utilizing GLP-1 RAs and SGLT-2 inhibitors in this population
